Kidney TransplantGut healthKidney and urinaryDrugPhase 4
What this study is
The purpose of this clinical trial is to find out whether a medication, called letermovir, can help prevent a virus called cytomegalovirus (CMV) in participants who receive a kidney or liver transplant and who have already been exposed the CMV.
Participants will take letermovir for 84 days.
What's being tested
- Letermovir
Intervention · DRUG
1 tablet by mouth, once daily, for 84 days
Study details
- Official title
- An Interventional Study of Letermovir for Primary Prophylaxis of Cytomegalovirus Infection in Moderate Risk (R+) Abdominal Solid Organ Transplant Recipients
- Sponsor
- University of Wisconsin, Madison
- Conditions
- Kidney Transplant · Liver Transplant
- Enrolling
- 146 people
- Starts
- 2026-10
- Est. completion
- 2029-09
- Design
- Open-label, single group, Phase 4
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 18 Years and overSex ALLHealthy volunteers Not acceptedYou may qualify if
- Adults who are at moderate risk for CMV after transplant (CMV IGG+, including D+/R+ or D-/R+)
- Adults who received a kidney transplant, liver transplant, or any combination thereof
You can't join if
- Known contraindication to letermovir or its excipients
- Current participation in another CMV related study
- Unwilling or unable to participate in the study protocol
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
1
Study locations (1)
1 openUniversity of Wisconsin - Madison
Madison, Wisconsin, United States
Study team
Sponsor
University of Wisconsin, Madison
Study ID 2026-0529
Principal investigator
David Al-Adra, MD
University of Wisconsin, Madison
CONTACT
Office of Clinical Research Department of Surgery
Have questions? The contacts above can answer them before you apply.
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.